ELIANA: CTL019 Shows High CR Rate in Pediatric/Young Adult Patients With Relapsed/Refractory B-Cell ALL

Slideset - Phase II trial suggests durable, MRD-negative CR in 82% of patients after infusion of CTL019 CAR T-cells.
Source: Clinical Care Options Leukemia - Category: Hematology Source Type: research